{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T12:56:12Z","timestamp":1781787372680,"version":"3.54.5"},"reference-count":109,"publisher":"Bentham Science Publishers Ltd.","issue":"8","funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["AN372\/29-1"],"award-info":[{"award-number":["AN372\/29-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["30-1"],"award-info":[{"award-number":["30-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>Type 2 diabetes mellitus (T2DM) is a set of metabolic disorders specified by hyperglycemia as a result of abnormalities in insulin secretion or sensitivity. Chronic kidney disease (CKD) and cardiovascular disease (CVD) are the widespread co-morbidities of T2DM and share risk factors for onset and progression. Despite numerous mono- and combination therapies exist, the progression of diabetes complications remains a global health concern. Treatment options for diabetic- CKD and CVD include drugs targeting hyperglycemia, hypertension, albuminuria, hyperlipidemia and the renin-angiotensin aldosterone system (RAAS). The sodium-glucose co-transporter 2 channel (SGLT2) is abundantly present in proximal tubules of the kidney and its capacity to recover glucose and sodium from the glomerular filtrate limits urinary glucose and sodium excretion. SGLT2 inhibitors (SGLT2i) reduce sodium and glucose reabsorption in the proximal and thus increase urinary glucose excretion in T2DM. SGLT2i monotherapy can improve but dual SGLT2\/RAAS inhibition or SGLT2i along with other classes of drugs are more effective in protecting the kidneys and the cardiovascular system in patients with and without diabetes. Combinations such as empagliflozin and linagliptin, ertugliflozin and metolazone, dapagliflozin and sacubitril- valsartan and many more show promising results. Here, we have reviewed the ongoing and completed clinical trials, addressed current theories, and discussed necessary future research to explain the possible risks and benefits of using an SGLT2i alone and in combination with existing antidiabetic drugs and drugs acting on the cardiovascular system.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573399819666220816145907","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T11:09:55Z","timestamp":1660734595000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors"],"prefix":"10.2174","volume":"19","author":[{"given":"Ajinath","family":"Kale","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Laboratory of Molecular Pharmacology, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan-333031, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshima","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Laboratory of Molecular Pharmacology, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan-333031, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine IV, Hospital of the Ludwig Maximilians University Munich, 80336 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Laboratory of Molecular Pharmacology, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan-333031, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.hjc.2018.04.008","volume":"61","author":"Tentolouris A.","year":"2020","unstructured":"Tentolouris A.; Eleftheriadou I.; Athanasakis K.; Prevalence of diabetes mellitus as well as cardiac and other main comorbidities in a representative sample of the adult Greek population in comparison with the general population. Hellenic J Cardiol 2020,61(1),15-22","journal-title":"Hellenic J Cardiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"k1497","DOI":"10.1136\/bmj.k1497","volume":"362","author":"Xu G.","year":"2018","unstructured":"Xu G.; Liu B.; Sun Y.; Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: Population based study. BMJ 2018,362,k1497","journal-title":"BMJ"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","volume":"72","author":"Zelniker T.A.","year":"2018","unstructured":"Zelniker T.A.; Braunwald E.; Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol 2018,72(15),1845-1855","journal-title":"J Am Coll Cardiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"Jha V.","year":"2013","unstructured":"Jha V.; Garcia-Garcia G.; Iseki K.; Chronic kidney disease: Global dimension and perspectives. Lancet 2013,382(9888),260-272","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.drudis.2021.04.007","volume":"26","author":"Kale A.","year":"2021","unstructured":"Kale A.; Sankrityayan H.; Anders H.J.; Bhanudas Gaikwad A.; Klotho: A possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes. Drug Discov Today 2021,26(8),1963-1971","journal-title":"Drug Discov Today"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","volume":"94","author":"Heerspink H.J.L.","year":"2018","unstructured":"Heerspink H.J.L.; Kosiborod M.; Inzucchi S.E.; Cherney D.Z.I.; Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018,94(1),26-39","journal-title":"Kidney Int"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"Wanner Ch.","year":"2016","unstructured":"Wanner Ch.; Inzucchi S.E.; Zinman B.; Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016,375(18),1801-1802","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"Neal B.","year":"2017","unstructured":"Neal B.; Perkovic V.; Mahaffey K.W.; Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017,377(7),644-657","journal-title":"N Engl J Med"},{"key":"ref=9","first-page":"155","volume":"9","author":"Hershon K.S.","year":"2016","unstructured":"Hershon K.S.; Options for empagliflozin in combination therapy in type 2 diabetes mellitus. Int J Gen Med 2016,9,155-172","journal-title":"Int J Gen Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11892-017-0853-8","volume":"17","author":"Grunberger G.","year":"2017","unstructured":"Grunberger G.; Should side effects influence the selection of antidiabetic therapies in type 2 diabetes? Curr Diab Rep 2017,17(4),21","journal-title":"Curr Diab Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"Rena G.","year":"2017","unstructured":"Rena G.; Hardie D.G.; Pearson E.R.; The mechanisms of action of metformin. Diabetologia 2017,60(9),1577-1585","journal-title":"Diabetologia"},{"key":"ref=12","unstructured":"Akmal M, Wadhwa R. StatPearls Publishing 2021; LLC: 2021."},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/10408444.2017.1351420","volume":"48","author":"Davidson M.A.","year":"2018","unstructured":"Davidson M.A.; Mattison D.R.; Azoulay L.; Krewski D.; Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: Past, present and future. Crit Rev Toxicol 2018,48(1),52-108","journal-title":"Crit Rev Toxicol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2337\/diab.26.5.445","volume":"26","author":"DeFronzo R.A.","year":"1977","unstructured":"DeFronzo R.A.; Andres R.; Bedsoe T.A.; Boden G.; Faloona G.A.; Tobin J.D.; A test of the hypothesis that the rate of fall in glucose concentration triggers counterregulatory hormonal responses in man. Diabetes 1977,26(5),445-452","journal-title":"Diabetes"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1681\/ASN.2016060650","volume":"28","author":"de Boer I.H.","year":"2017","unstructured":"de Boer I.H.; Kahn S.E.; SGLT2 inhibitors-sweet success for diabetic kidney disease? J Am Soc Nephrol 2017,28(1),7-10","journal-title":"J Am Soc Nephrol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2337\/dc13-0467","volume":"37","author":"Jabbour S.A.","year":"2014","unstructured":"Jabbour S.A.; Hardy E.; Sugg J.; Parikh S.; Group S.; Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014,37(3),740-750","journal-title":"Diabetes Care"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/00325481.2019.1581971","volume":"131","author":"Filippatos T.D.","year":"2019","unstructured":"Filippatos T.D.; Liontos A.; Papakitsou I.; Elisaf M.S.; SGLT2 inhibitors and cardioprotection: A matter of debate and multiple hypotheses. Postgrad Med 2019,131(2),82-88","journal-title":"Postgrad Med"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"e00303","DOI":"10.1002\/edm2.303","volume":"5","author":"Seidu S.","year":"2022","unstructured":"Seidu S.; Kunutsor S.K.; Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab 2022,5(1),e00303","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.2337\/dc18-0680","volume":"41","author":"Jabbour S.A.","year":"2018","unstructured":"Jabbour S.A.; Fr\u00edas J.P.; Hardy E.; Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. Diabetes Care 2018,41(10),2136-2146","journal-title":"Diabetes Care"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","volume":"93","author":"Cherney D.Z.I.","year":"2018","unstructured":"Cherney D.Z.I.; Cooper M.E.; Tikkanen I.; Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 2018,93(1),231-244","journal-title":"Kidney Int"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fendo.2018.00412","volume":"9","author":"Han E.","year":"2018","unstructured":"Han E.; Shin E.; Kim G.; Combining SGLT2 inhibition with a thiazolidinedione additively attenuate the very early phase of diabetic nephropathy progression in type 2 diabetes mellitus. Front Endocrinol (Lausanne) 2018,9,412","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"Alicic R.Z.","year":"2017","unstructured":"Alicic R.Z.; Rooney M.T.; Tuttle K.R.; Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol 2017,12(12),2032-2045","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","volume":"12","author":"Thomas M.C.","year":"2016","unstructured":"Thomas M.C.; Cooper M.E.; Zimmet P.; Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 2016,12(2),73-81","journal-title":"Nat Rev Nephrol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"Gansevoort R.T.","year":"2013","unstructured":"Gansevoort R.T.; Correa-Rotter R.; Hemmelgarn B.R.; Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 2013,382(9889),339-352","journal-title":"Lancet"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000506634","volume":"6","author":"Chen Y.","year":"2020","unstructured":"Chen Y.; Lee K.; Ni Z.; He J.C.; Diabetic kidney disease: Challenges, advances, and opportunities. Kidney Dis 2020,6(4),215-225","journal-title":"Kidney Dis"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2174\/1574886313666180226103408","volume":"13","author":"Singh M.","year":"2018","unstructured":"Singh M.; Kumar A.; Risks associated with SGLT2 inhibitors: An overview. Curr Drug Saf 2018,13(2),84-91","journal-title":"Curr Drug Saf"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.2337\/dc13-2036","volume":"37","author":"Andr\u00e9sd\u00f3ttir G.","year":"2014","unstructured":"Andr\u00e9sd\u00f3ttir G.; Jensen M.L.; Carstensen B.; Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care 2014,37(6),1660-1667","journal-title":"Diabetes Care"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2011.861","volume":"305","author":"de Boer I.H.","year":"2011","unstructured":"de Boer I.H.; Rue T.C.; Hall Y.N.; Heagerty P.J.; Weiss N.S.; Himmelfarb J.; Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011,305(24),2532-2539","journal-title":"JAMA"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1053\/j.ajkd.2013.10.047","volume":"63","author":"Badal S.S.","year":"2014","unstructured":"Badal S.S.; Danesh F.R.; New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis 2014,63(2)(Suppl. 2),S63-S83","journal-title":"Am J Kidney Dis"},{"key":"ref=30","first-page":"268","volume":"7","author":"Zakkerkish M.","year":"2013","unstructured":"Zakkerkish M.; Shahbazian H.B.; Shahbazian H.; Latifi S.M.; Moravej Aleali A.; Albuminuria and its correlates in type 2 diabetic patients. Iran J Kidney Dis 2013,7(4),268-276","journal-title":"Iran J Kidney Dis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1681\/ASN.2006080872","volume":"18","author":"Perkins B.A.","year":"2007","unstructured":"Perkins B.A.; Ficociello L.H.; Ostrander B.E.; Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007,18(4),1353-1361","journal-title":"J Am Soc Nephrol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"Adler A.I.","year":"2003","unstructured":"Adler A.I.; Stevens R.J.; Manley S.E.; Bilous R.W.; Cull C.A.; Holman R.R.; Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003,63(1),225-232","journal-title":"Kidney Int"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"Thomas M.C.","year":"2015","unstructured":"Thomas M.C.; Brownlee M.; Susztak K.; Diabetic kidney disease. Nat Rev Dis Primers 2015,1,15018","journal-title":"Nat Rev Dis Primers"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","volume":"21","author":"P\u00e1lsson R.","year":"2014","unstructured":"P\u00e1lsson R.; Patel U.D.; Cardiovascular complications of diabetic kidney disease. Adv Chronic Kidney Dis 2014,21(3),273-280","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.20452\/pamw.504","volume":"118","author":"Gaede P.","year":"2008","unstructured":"Gaede P.; Intensive glucose control and cardiovascular disease in type 2 diabetes-should we change the recommended target for glycated hemoglobin? Commentary to ACCORD and ADVANCE trials. Pol Arch Med Wewn 2008,118(11),619-621","journal-title":"Pol Arch Med Wewn"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/nep.13860","volume":"26","author":"Sugahara M.","year":"2021","unstructured":"Sugahara M.; Pak W.L.W.; Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology (Carlton) 2021,26(6),491-500","journal-title":"Nephrology (Carlton)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/archinternmed.2011.2230","volume":"172","author":"Coca S.G.","year":"2012","unstructured":"Coca S.G.; Ismail-Beigi F.; Haq N.; Krumholz H.M.; Parikh C.R.; Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: Systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012,172(10),761-769","journal-title":"Arch Intern Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"CD009122","DOI":"10.1002\/14651858.CD009122.pub2","volume":"2014","author":"Fullerton B.","year":"2014","unstructured":"Fullerton B.; Jeitler K.; Seitz M.; Horvath K.; Berghold A.; Siebenhofer A.; Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014,2014(2),CD009122","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2014.18574","volume":"313","author":"Emdin C.A.","year":"2015","unstructured":"Emdin C.A.; Rahimi K.; Neal B.; Callender T.; Perkovic V.; Patel A.; Blood pressure lowering in type 2 diabetes: A systematic review and meta-analysis. JAMA 2015,313(6),603-615","journal-title":"JAMA"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","volume":"366","author":"Casas J.P.","year":"2005","unstructured":"Casas J.P.; Chua W.; Loukogeorgakis S.; Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 2005,366(9502),2026-2033","journal-title":"Lancet"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","volume":"123","author":"Tobe S.W.","year":"2011","unstructured":"Tobe S.W.; Clase C.M.; Gao P.; Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: Results from the ONTARGET and TRANSCEND studies. Circulation 2011,123(10),1098-1107","journal-title":"Circulation"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","volume":"51","author":"Bomback A.S.","year":"2008","unstructured":"Bomback A.S.; Kshirsagar A.V.; Amamoo M.A.; Klemmer P.J.; Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am J Kidney Dis 2008,51(2),199-211","journal-title":"Am J Kidney Dis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.4065\/82.11.1381","volume":"82","author":"Agarwal R.","year":"2007","unstructured":"Agarwal R.; Effects of statins on renal function. Mayo Clin Proc 2007,82(11),1381-1390","journal-title":"Mayo Clin Proc"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.7326\/0003-4819-145-2-200607180-00009","volume":"145","author":"Douglas K.","year":"2006","unstructured":"Douglas K.; O\u2019Malley P.G.; Jackson J.L.; Meta-analysis: The effect of statins on albuminuria. Ann Intern Med 2006,145(2),117-124","journal-title":"Ann Intern Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","volume":"79","author":"Pereira M.J.","year":"2019","unstructured":"Pereira M.J.; Eriksson J.W.; Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs 2019,79(3),219-230","journal-title":"Drugs"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1053\/ajkd.2003.50039","volume":"41","author":"Morales E.","year":"2003","unstructured":"Morales E.; Valero M.A.; Le\u00f3n M.; Hern\u00e1ndez E.; Praga M.; Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003,41(2),319-327","journal-title":"Am J Kidney Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1470320314550018","volume":"16","author":"Tylicki L","year":"2015","unstructured":"Tylicki L; Jakubowska A; Lizakowski S; \u015awietlik D; Rutkowski B; Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study. J Renin Angiotensin Aldosterone Syst 2015,16(1),145-152","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","volume":"28","author":"Rossing K.","year":"2005","unstructured":"Rossing K.; Schjoedt K.J.; Smidt U.M.; Boomsma F.; Parving H.H.; Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 2005,28(9),2106-2112","journal-title":"Diabetes Care"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"van den Meiracker A.H.","year":"2006","unstructured":"van den Meiracker A.H.; Baggen R.G.; Pauli S.; Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006,24(11),2285-2292","journal-title":"J Hypertens"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"Kolkhof P.","year":"2021","unstructured":"Kolkhof P.; Hartmann E.; Freyberger A.; Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol 2021,52(8),642-652","journal-title":"Am J Nephrol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.semnephrol.2012.07.006","volume":"32","author":"Doria A.","year":"2012","unstructured":"Doria A.; Niewczas M.A.; Fiorina P.; Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy? Semin Nephrol 2012,32(5),437-444","journal-title":"Semin Nephrol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"7356","DOI":"10.3892\/mmr.2018.8776","volume":"17","author":"Yin D.D.","year":"2018","unstructured":"Yin D.D.; Luo J.H.; Zhao Z.Y.; Liao Y.J.; Li Y.; Tranilast prevents renal interstitial fibrosis by blocking mast cell infiltration in a rat model of diabetic kidney disease. Mol Med Rep 2018,17(5),7356-7364","journal-title":"Mol Med Rep"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ki.2011.33","volume":"79","author":"Trachtman H.","year":"2011","unstructured":"Trachtman H.; Fervenza F.C.; Gipson D.S.; A phase 1, single-dose study of fresolimumab, an anti-TGF-\u03b2 antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011,79(11),1236-1243","journal-title":"Kidney Int"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1517\/14728222.2012.703657","volume":"16","author":"Moreno J.A.","year":"2012","unstructured":"Moreno J.A.; Moreno S.; Rubio-Navarro A.; Targeting chemokines in proteinuria-induced renal disease. Expert Opin Ther Targets 2012,16(8),833-845","journal-title":"Expert Opin Ther Targets"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"F1288","DOI":"10.1152\/ajprenal.00316.2013","volume":"305","author":"Sullivan T.","year":"2013","unstructured":"Sullivan T.; Miao Z.; Dairaghi D.J.; CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am J Physiol Renal Physiol 2013,305(9),F1288-F1297","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000504623","volume":"6","author":"Raina R.","year":"2020","unstructured":"Raina R.; Chauvin A.; Chakraborty R.; The role of endothelin and endothelin antagonists in chronic kidney disease. Kidney Dis 2020,6(1),22-34","journal-title":"Kidney Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/jcm9030824","volume":"9","author":"Enevoldsen F.C.","year":"2020","unstructured":"Enevoldsen F.C.; Sahana J.; Wehland M.; Grimm D.; Infanger M.; Kr\u00fcger M.; Endothelin receptor antagonists: Status quo and future perspectives for targeted therapy. J Clin Med 2020,9(3),824","journal-title":"J Clin Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41581-019-0248-y","volume":"16","author":"Ruiz-Ortega M.","year":"2020","unstructured":"Ruiz-Ortega M.; Rayego-Mateos S.; Lamas S.; Ortiz A.; Rodrigues-Diez R.R.; Targeting the progression of chronic kidney disease. Nat Rev Nephrol 2020,16(5),269-288","journal-title":"Nat Rev Nephrol"},{"key":"ref=59","doi-asserted-by":"crossref","unstructured":"Balogh D, Hodrea J, Hosszu A, et al. MO620 antifibrotic effects of SGLT2 inhibition in the kidney and proximal tubular cells. Nephrol Dial Transplant 2021; 36(Supplement_1): gfab093.001.","DOI":"10.1093\/ndt\/gfab093.001"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/antiox10020246","volume":"10","author":"Kawanami D.","year":"2021","unstructured":"Kawanami D.; Takashi Y.; Takahashi H.; Motonaga R.; Tanabe M.; Renoprotective effects of DPP-4 inhibitors. Antioxidants 2021,10(2),246","journal-title":"Antioxidants"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000514286","volume":"46","author":"Galu\u0161ka D.","year":"2021","unstructured":"Galu\u0161ka D.; P\u00e1cal L.; Ka\u0148kov\u00e1 K. Pathophysiological implication of vitamin D in diabetic kidney disease. Kidney Blood Press Res 2021,46(2),152-161","journal-title":"Kidney Blood Press Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1751-7176.2010.00336.x","volume":"12","author":"Gruson D.","year":"2010","unstructured":"Gruson D.; Rousseau M.F.; Ketelslegers J.M.; Hermans M.P.; Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype. J Clin Hypertens (Greenwich) 2010,12(8),653-660","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1124\/jpet.120.265496","volume":"374","author":"Ozoux M-L.","year":"2020","unstructured":"Ozoux M-L.; Briand V.; Pelat M.; Potential therapeutic value of urotensin II receptor antagonist in chronic kidney disease and associated comorbidities. J Pharmacol Exp Ther 2020,374(1),24-37","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"F1276","DOI":"10.1152\/ajprenal.00396.2014","volume":"308","author":"Gorin Y.","year":"2015","unstructured":"Gorin Y.; Cavaglieri R.C.; Khazim K.; Targeting NADPH oxidase with a novel dual Nox1\/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Renal Physiol 2015,308(11),F1276-F1287","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"74217","DOI":"10.18632\/oncotarget.18540","volume":"8","author":"Kwon G.","year":"2017","unstructured":"Kwon G.; Uddin M.J.; Lee G.; A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: Possible role of peroxisomal and mitochondrial biogenesis. Oncotarget 2017,8(43),74217-74232","journal-title":"Oncotarget"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"3797802","DOI":"10.1155\/2017\/3797802","volume":"2017","author":"Cui W.","year":"2017","unstructured":"Cui W.; Min X.; Xu X.; Du B.; Luo P.; Role of nuclear factor erythroid 2-related factor 2 in diabetic nephropathy. J Diabetes Res 2017,2017,3797802","journal-title":"J Diabetes Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s10157-020-01917-5","volume":"24","author":"Kanda H.","year":"2020","unstructured":"Kanda H.; Yamawaki K.; Bardoxolone methyl: Drug development for diabetic kidney disease. J Clin Exp Nephrol 2020,24(10),857-864","journal-title":"J Clin Exp Nephrol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"118644","DOI":"10.1016\/j.lfs.2020.118644","volume":"264","author":"Kale A.","year":"2021","unstructured":"Kale A.; Sankrityayan H.; Anders H-J.; Gaikwad A.B.; Epigenetic and non-epigenetic regulation of Klotho in kidney disease. Life Sci 2021,264,118644","journal-title":"Life Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1590\/2175-8239-jbn-2018-0165","volume":"41","author":"Nascimento L.R.D.","year":"2019","unstructured":"Nascimento L.R.D.; Domingueti C.P.; MicroRNAs: New biomarkers and promising therapeutic targets for diabetic kidney disease. J Bras Nefrol 2019,41(3),412-422","journal-title":"J Bras Nefrol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.12659\/MSM.900938","volume":"22","author":"Zhu X.","year":"2016","unstructured":"Zhu X.; Zhang C.; Fan Q.; Inhibiting microRNA-503 and microRNA-181d with losartan ameliorates diabetic nephropathy in KKAy mice. Med Sci Monit 2016,22,3902-3909","journal-title":"Med Sci Monit"},{"key":"ref=71","first-page":"4952","volume":"21","author":"Xu X.H.","year":"2017","unstructured":"Xu X.H.; Ding D.F.; Yong H.J.; Resveratrol transcriptionally regulates miRNA-18a-5p expression ameliorating diabetic nephropathy via increasing autophagy. Eur Rev Med Pharmacol Sci 2017,21(21),4952-4965","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/jcp.26092","volume":"233","author":"Han F.","year":"2018","unstructured":"Han F.; Wang S.; Chang Y.; Triptolide prevents extracellular matrix accumulation in experimental diabetic kidney disease by targeting microRNA\u2010137\/Notch1 pathway. J of Cel Phyysiol 2018,233(3),2225-2237","journal-title":"J of Cel Phyysiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ymthe.2016.08.001","volume":"25","author":"K\u00f6lling M.","year":"2017","unstructured":"K\u00f6lling M.; Kaucsar T.; Schauerte C.; Therapeutic miR-21 silencing ameliorates diabetic kidney disease in mice. Mol Ther 2017,25(1),165-180","journal-title":"Mol Ther"},{"key":"ref=74","first-page":"653789","volume":"2013","author":"Matheus A.S.M.M.","year":"2013","unstructured":"Matheus A.S.M.M.; Tannus L.R.M.; Cobas R.A.; Palma C.C.S.; Negrato C.A.; Gomes M.B.; Impact of diabetes on cardiovascular disease: An update. Int J Hypertens 2013,2013,653789","journal-title":"Int J Hypertens"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","volume":"6","author":"Leon B.M.","year":"2015","unstructured":"Leon B.M.; Maddox T.M.; Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 2015,6(13),1246-1258","journal-title":"World J Diabetes"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","volume":"17","author":"Ormazabal V.","year":"2018","unstructured":"Ormazabal V.; Nair S.; Elfeky O.; Aguayo C.; Salomon C.; Zu\u00f1iga F.A.; Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018,17(1),122","journal-title":"Cardiovasc Diabetol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2337\/diabetes.52.7.1799","volume":"52","author":"Duncan B.B.","year":"2003","unstructured":"Duncan B.B.; Schmidt M.I.; Pankow J.S.; Low-grade systemic inflammation and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes 2003,52(7),1799-1805","journal-title":"Diabetes"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"Shoelson S.E.","year":"2006","unstructured":"Shoelson S.E.; Lee J.; Goldfine A.B.; Inflammation and insulin resistance. J Clin Invest 2006,116(7),1793-1801","journal-title":"J Clin Invest"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.yjmcc.2008.05.006","volume":"45","author":"Kim M.","year":"2008","unstructured":"Kim M.; Oh J.K.; Sakata S.; Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008,45(2),270-280","journal-title":"J Mol Cell Cardiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s12011-014-0155-9","volume":"163","author":"Rogoveanu O-C","year":"2015","unstructured":"Rogoveanu O-C; Mogo\u015fanu GD; Bejenaru C; Effects of calcium fructoborate on levels of C-reactive protein, total cholesterol, low-density lipoprotein, triglycerides, IL-1\u03b2 IL-6, and MCP-1: A double-blind, placebo-controlled clinical study. Biol Trace Elem Res 2015,163(1-2),124-131","journal-title":"Biol Trace Elem Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.lfs.2019.02.027","volume":"221","author":"Malek V.","year":"2019","unstructured":"Malek V.; Sharma N.; Sankrityayan H.; Gaikwad A.B.; Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy. Life Sci 2019,221,159-167","journal-title":"Life Sci"},{"key":"ref=82","first-page":"531","volume":"19","author":"Mohamadshahi M.","year":"2014","unstructured":"Mohamadshahi M.; Veissi M.; Haidari F.; Javid A.Z.; Mohammadi F.; Shirbeigi E.; Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: A randomized controlled clinical trial. J Res Med Sci 2014,19(6),531-536","journal-title":"J Res Med Sci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"652","DOI":"10.2337\/dc09-1936","volume":"33","author":"Prince C.T.","year":"2010","unstructured":"Prince C.T.; Secrest A.M.; Mackey R.H.; Arena V.C.; Kingsley L.A.; Orchard T.J.; Cardiovascular autonomic neuropathy, HDL cholesterol, and smoking correlate with arterial stiffness markers determined 18 years later in type 1 diabetes. Diabetes Care 2010,33(3),652-657","journal-title":"Diabetes Care"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1076029619845056","DOI":"10.1177\/1076029619845056","volume":"25","author":"Fiodorenko-Dumas \u017b","year":"2019","unstructured":"Fiodorenko-Dumas \u017b; Dumas I; Mastej K; Receptor GP IIb\/IIIa as an indicator of risk in vascular events. Clin Appl Thromb Hemost 2019,25,1076029619845056","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"e0223171","DOI":"10.1371\/journal.pone.0223171","volume":"14","author":"Addai-Mensah O.","year":"2019","unstructured":"Addai-Mensah O.; Annani-Akollor M.E.; Nsafoah F.O.; Effect of poor glycaemic control on plasma levels and activity of protein C, protein S, and antithrombin III in type 2 diabetes mellitus. PLoS One 2019,14(9),e0223171","journal-title":"PLoS One"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/CIRCULATIONAHA.106.634949","volume":"115","author":"Vinik A.I.","year":"2007","unstructured":"Vinik A.I.; Ziegler D.; Diabetic cardiovascular autonomic neuropathy. Circulation 2007,115(3),387-397","journal-title":"Circulation"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1042\/CS20080500","volume":"116","author":"Asghar O.","year":"2009","unstructured":"Asghar O.; Al-Sunni A.; Khavandi K.; Diabetic cardiomyopathy. Clin Sci (Lond) 2009,116(10),741-760","journal-title":"Clin Sci (Lond)"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/hrt.2007.128769","volume":"94","author":"Tribouilloy C.","year":"2008","unstructured":"Tribouilloy C.; Rusinaru D.; Mahjoub H.; Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: A prospective five-year study. Heart 2008,94(11),1450-1455","journal-title":"Heart"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"Baggio L.L.","year":"2007","unstructured":"Baggio L.L.; Drucker D.J.; Biology of incretins: GLP-1 and GIP. Gastroenterology 2007,132(6),2131-2157","journal-title":"Gastroenterology"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"Drucker D.J.","year":"2006","unstructured":"Drucker D.J.; The biology of incretin hormones. Cell Metab 2006,3(3),153-165","journal-title":"Cell Metab"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"103810","DOI":"10.1016\/j.bioorg.2020.103810","volume":"99","author":"Deng X.","year":"2020","unstructured":"Deng X.; Tavallaie M.S.; Sun R.; Drug discovery approaches targeting the incretin pathway. Bioorg Chem 2020,99,103810","journal-title":"Bioorg Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"Brown E.","year":"2021","unstructured":"Brown E.; Heerspink H.J.L.; Cuthbertson D.J.; Wilding J.P.H.; SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications. Lancet 2021,398(10296),262-276","journal-title":"Lancet"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S2213-8587(17)30033-5","volume":"5","author":"Standl E.","year":"2017","unstructured":"Standl E.; Schnell O.; McGuire D.K.; Ceriello A.; Ryd\u00e9n L.; Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol 2017,5(5),391-402","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.bbadis.2014.06.004","volume":"1842","author":"Wronkowitz N.","year":"2014","unstructured":"Wronkowitz N.; G\u00f6rgens S.W.; Romacho T.; Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim Biophys Acta 2014,1842(9),1613-1621","journal-title":"Biochim Biophys Acta"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12933-019-0965-3","volume":"18","author":"Chihara A.","year":"2019","unstructured":"Chihara A.; Tanaka A.; Morimoto T.; Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: A secondary analysis of the REASON trial. Cardiovasc Diabetol 2019,18(1),158","journal-title":"Cardiovasc Diabetol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nature09580","volume":"468","author":"Watanabe A.","year":"2010","unstructured":"Watanabe A.; Choe S.; Chaptal V.; The mechanism of sodium and substrate release from the binding pocket of vSGLT. Nature 2010,468(7326),988-991","journal-title":"Nature"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"Ferrannini E.","year":"2014","unstructured":"Ferrannini E.; Muscelli E.; Frascerra S.; Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014,124(2),499-508","journal-title":"J Clin Invest"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","volume":"21","author":"Bonner C.","year":"2015","unstructured":"Bonner C.; Kerr-Conte J.; Gmyr V.; Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015,21(5),512-517","journal-title":"Nat Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B.; Wanner C.; Lachin J.M.; Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015,373(22),2117-2128","journal-title":"N Engl J Med"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"Wiviott S.D.","year":"2019","unstructured":"Wiviott S.D.; Raz I.; Bonaca M.P.; Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019,380(4),347-357","journal-title":"N Engl J Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"Cannon C.P.","year":"2020","unstructured":"Cannon C.P.; Pratley R.; Dagogo-Jack S.; Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020,383(15),1425-1435","journal-title":"N Engl J Med"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"Bhatt D.L.","year":"2021","unstructured":"Bhatt D.L.; Szarek M.; Pitt B.; Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021,384(2),129-139","journal-title":"N Engl J Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"Bhatt D.L.","year":"2021","unstructured":"Bhatt D.L.; Szarek M.; Steg P.G.; Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021,384(2),117-128","journal-title":"N Engl J Med"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"Seidah N.G.","year":"2014","unstructured":"Seidah N.G.; Awan Z.; Chr\u00e9tien M.; Mbikay M.; PCSK9: A key modulator of cardiovascular health. Circ Res 2014,114(6),1022-1036","journal-title":"Circ Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","volume":"396","author":"Vaduganathan M.","year":"2020","unstructured":"Vaduganathan M.; Claggett B.L.; Jhund P.S.; Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: A comparative analysis of three randomised controlled trials. Lancet 2020,396(10244),121-128","journal-title":"Lancet"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1194\/jlr.M051326","volume":"55","author":"K\u00fchnast S.","year":"2014","unstructured":"K\u00fchnast S.; van der Hoorn J.W.A.; Pieterman E.J.; Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res 2014,55(10),2103-2112","journal-title":"J Lipid Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"9820","DOI":"10.1073\/pnas.0903849106","volume":"106","author":"Chan J.C.","year":"2009","unstructured":"Chan J.C.; Piper D.E.; Cao Q.; A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009,106(24),9820-9825","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.tcm.2019.05.007","volume":"30","author":"Warden B.A.","year":"2020","unstructured":"Warden B.A.; Fazio S.; Shapiro M.D.; The PCSK9 revolution: Current status, controversies, and future directions. Trends Cardiovasc Med 2020,30(3),179-185","journal-title":"Trends Cardiovasc Med"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pathol.2018.10.012","volume":"51","author":"Blanchard V.","year":"2019","unstructured":"Blanchard V.; Khantalin I.; Ramin-Mangata S.; Ch\u00e9mello K.; Nativel B.; Lambert G.; PCSK9: From biology to clinical applications. Pathology 2019,51(2),177-183","journal-title":"Pathology"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399819666220816145907","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207546\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399819666220816145907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T22:42:02Z","timestamp":1727822522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207546\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":109,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399819666220816145907","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e160822207546"}}